NCT05068232
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
Recruiting
PHASE2Ages 18+InterventionalTreatmentUniversity of ChicagoInvestigator-initiated
~49 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:Ablative RadiationDurvalumabEtoposideCarboplatin
At a glance
Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression-Free Survival of Participant Until Disease Progression or Death
Measured over 48 months
Conditions
Where it's being run
2 sites across 2 statesIllinois1
Wisconsin1
Study leadership
- Christine Bestvina, MD · PRINCIPAL_INVESTIGATOR · University of Chicago - Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression-Free Survival of Participant Until Disease Progression or Death48 months
The progression-free survival (PFS) of subjects with extensive-stage small cell lung cancer treated with durvalumab, carboplatin and etoposide with hypofractionated ablative radiation therapy. Progression-free survival will be defined as the time from start of treatment until disease progression per Response Evaluation Criteria in Solid Tumors (RECISTv1.1) or death from any cause.